Genomic architecture of pharmacological efficacy and adverse events

Aparna Chhibber, Deanna L. Kroetz, Kelan G. Tantisira, Michael Mcgeachie, Cheng Cheng, Robert Plenge, Eli Stahl, Wolfgang Sadee, Marylyn D. Ritchie, Sarah A. Pendergrass

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


The pharmacokinetic and pharmacodynamic disciplines address pharmacological traits, including efficacy and adverse events. Pharmacogenomics studies have identified pervasive genetic effects on treatment outcomes, resulting in the development of genetic biomarkers for optimization of drug therapy. Pharmacogenomics-based tests are already being applied in clinical decision making. However, despite substantial progress in identifying the genetic etiology of pharmacological response, current biomarker panels still largely rely on single gene tests with a large portion of the genetic effects remaining to be discovered. Future research must account for the combined effects of multiple genetic variants, incorporate pathway-based approaches, explore gene-gene interactions and nonprotein coding functional genetic variants, extend studies across ancestral populations, and prioritize laboratory characterization of molecular mechanisms. Because genetic factors can play a key role in drug response, accurate biomarker tests capturing the main genetic factors determining treatment outcomes have substantial potential for improving individual clinical care.

Original languageEnglish (US)
Pages (from-to)2025-2048
Number of pages24
Issue number16
StatePublished - Dec 1 2014

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Pharmacology


Dive into the research topics of 'Genomic architecture of pharmacological efficacy and adverse events'. Together they form a unique fingerprint.

Cite this